Breaking the NPP small-volume bottleneck: how PatientsForce's global drug-sourcing service fills the clinical gap

'Doctor Chen, is there really no other medicine?' Facing a family's anxious tears, Dr. Chen felt helpless. He knew a targeted therapy precisely matching this patient's mutation had just been approved abroad — but it held no license in Taiwan. To save a life he initiated a special import, only to spend the following weeks mired in regulatory paperwork and a hunt for overseas supply.

This is no isolated case: it is the drug-seeking dilemma playing out daily in Taiwan's clinics. Industry statistics put Taiwan's average new-drug launch 12 to 24 months behind Europe and the US — longer still for certain rare diseases and special cancers. Every year, thousands of patients racing against time find standard treatments exhausted.

When conventional routes fail, physicians turn to the Named Patient Program (NPP) — case-by-case special import. Yet this well-intentioned, life-saving regulatory channel is hard to execute in practice.

The clinical pain point: why do case-based imports keep hitting walls?

NPP's patient-centered core is precisely its biggest supply-chain pain:

• Market failure of tiny volumes: an NPP case usually serves one or very few patients — sometimes only a few packs. For traditional large distributors, such micro-orders have no economy of scale.
• High administrative and time costs: for those few packs, a distributor must invest heavily in sourcing, cross-border logistics, cold-chain qualification and TFDA's strict special-import review.
• A thankless equation: squeezed between thin margins and heavy administration, most distributors decline NPP cases — leaving willing physicians unable to find anyone to import.

For pharma companies, when a key opinion leader raises such a niche request, internal constraints often force a polite refusal — a lost opportunity to build a deep bond with the physician.

The PatientsForce answer: a flexible hub for global sourcing and compliant import

Seeing both dilemmas, PatientsForce launched the Taiwan special-import (EAP/NPP) support program — determined to be the party willing to take on the challenge.

1. International distribution links for flexible-volume supply

Behind every NPP case is an anxious life. PatientsForce has built strategic partnerships with international pharmaceutical distributors and supply platforms across the US, Europe and Asia. Through this global network we can flexibly match legitimate sources to the required volume, breaking the traditional 'too small to serve' constraint.

2. One-stop TFDA-compliant import application

Special import is not cross-border online shopping — it is a rigorous regulatory campaign. Our regulatory affairs and project management teams support the full process: helping physicians prepare the protocol (Form A / Form B), assembling manufacturer documentation, and interfacing with TFDA for approval — returning precious time to clinical care.

3. Filling big pharma's long-tail service gap

When a KOL asks about a non-core product, an orphan drug or a tiny-volume NPP need, you no longer have to say 'sorry' — you can say 'let the PatientsForce team help'. As your external special-operations unit, we handle these administratively heavy, scattered cases, securing your key physician relationships and channel trust.

Your pain point, our answer

Global drug sourcing is more than logistics — it is a commitment to life and the highest support for physicians' professional judgment. We would be glad to arrange a short online exchange to show how our global resource network solves the small-volume import problems that give the industry headaches.